➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Colorcon
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,342,866

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,342,866
Title:Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
Abstract: Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to .gamma..delta.T-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
Inventor(s): Woodside; Darren G. (Houston, TX), Vanderslice; Peter (Houston, TX), Marathi; Upendra K. (Houston, TX)
Assignee: 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX)
Application Number:15/140,711
Patent Claims:see list of patent claims

Details for Patent 10,342,866

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial 7 HILLS INTERESTS LLC (Houston, TX) TEXAS HEART INSTITUTE (Houston, TX) 2035-04-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
AstraZeneca
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.